Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies

Atreya R, Ferrante M, Panaccione R, Feagan B, Shchukina O, Jairath V, Rieder F, Hisamatsu T, Siegmund B, Kligys K, Song A, Zambrano J, Mallick M, Zhang Y, Armuzzi A, D'Haens G (2025)

Publication Language: English

Publication Type: Journal article

Publication year: 2025

Journal

Journal of Crohns & Colitis Elsevier

Book Volume: 19

Article Number: jjae164

Journal Issue: 4

DOI: 10.1093/ecco-jcc/jjae164

Abstract

Background and Aims: Normalization of high-sensitivity C-reactive protein (hs-CRP) and fecal calprotectin (FCP) are suggested as intermediate treatment targets for Crohn's disease (CD). This analysis evaluates achievement of biomarker normalization and the relationship between improvements in biomarker concentrations and clinical and endoscopic outcomes among patients treated with risankizumab. Methods: This post hoc analysis included patients with moderately to severely active CD and elevated baseline hs-CRP (>5 mg/L) or FCP (>250 μg/g) concentrations from the 12-week ADVANCE and MOTIVATE induction studies, and the 52-week FORTIFY maintenance study. We assessed the proportion of patients achieving biomarker normalization, defined as hs-CRP ≤5 mg/L and FCP ≤250 μg/g, and the association between achieving biomarker normalization and improved clinical and endoscopic outcomes. Results: Among 748 patients with elevated baseline hs-CRP or FCP concentrations, higher proportions of patients treated with risankizumab vs placebo achieved normalization of hs-CRP (Week 12: placebo, 17.5%; risankizumab 600 mg, 48.5%; Week 52: placebo, 29.5%; risankizumab 180 mg, 45.2%; risankizumab 360 mg, 40.8%) and FCP (Week 12: placebo, 9.1%; risankizumab 600 mg, 26.0%; Week 52: placebo, 28.0%; risankizumab 180 mg, 43.0%; risankizumab 360 mg, 44.0%; nominal p < 0.05 vs placebo for all comparisons). Achievement of both clinical or endoscopic outcomes and improvement of biomarker concentrations occurred at higher rates among patients treated with risankizumab vs placebo, regardless of prior exposure to biologic therapies. Conclusions: Risankizumab treatment led to sustained normalization of inflammatory biomarkers with improved clinical and endoscopic results. Clinical Trial Registration Number: ADVANCE, NCT03105128; MOTIVATE, NCT03104413; FORTIFY, NCT03105102.

Authors with CRIS profile

Raja Atreya Professur für Translationale Immunforschung bei chronisch entzündlichen Darmerkrankungen

Involved external institutions

University Hospital Leuven (UZ) / Universitaire ziekenhuizen Leuven BE Belgium (BE) University of Calgary CA Canada (CA) Western University CA Canada (CA) First Pavlov State Medical University of St. Petersburg RU Russian Federation (RU) Cleveland Clinic US United States (USA) (US) Amsterdam University Medical Centers (Amsterdam UMC) / Amsterdam Universitair Medische Centra NL Netherlands (NL) Kyorin University / 杏林大学 JP Japan (JP) Charité - Universitätsmedizin Berlin DE Germany (DE) AbbVie Inc. US United States (USA) (US) Humanitas Research Hospital / IRCCS Istituto Clinico Humanitas IT Italy (IT)

How to cite

APA:

Atreya, R., Ferrante, M., Panaccione, R., Feagan, B., Shchukina, O., Jairath, V.,... D'Haens, G. (2025). Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies. Journal of Crohns & Colitis, 19(4). https://doi.org/10.1093/ecco-jcc/jjae164

MLA:

Atreya, Raja, et al. "Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies." Journal of Crohns & Colitis 19.4 (2025).

BibTeX: Download